Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
REGN
STRONG BUYAPPROVERegeneron Pharmaceuticals, Inc. · Healthcare · United States · $68.8B · Avg Vol: $705M/d
Regeneron clears the calibrated bar. All three legs are above the floor (Q69 V52 M52) and a buyback retiring 2.43% of shares provides substantial corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q69 is the strongest part of the case.
COMPANY DESCRIPTION
Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious diseases, with a strong presence in areas like eye diseases, allergic/inflammatory conditions, and oncology. The company's proprietary VelocImmune antibody discovery platform and robust R&D capabilities enable the creation of blockbuster biologic drugs, establishing a significant competitive moat through intellectual property and scientific leadership. Regeneron's integrated approach from research to commercialization underpins its success.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.2B | 13.1B | 14.2B | 14.3B | 5.6% | 14.9B | 16.7B | 17.8B | 11.5% |
| EPS | 40.51 | 37.05 | 40.90 | 43.07 | 2.1% | 40.67 | 48.97 | 54.27 | 12.3% |
| Shares | 109.6M | 109.4M | 109.6M | 105.7M | -3.5% | 103.0M | — | — | — |
| Debt | 2.7B | 2.7B | 2.7B | 2.7B | 0.1% | 2.7B | — | — | — |
| Equity | 22.7B | 26.0B | 29.4B | 31.3B | 11.3% | — | — | — | — |
| Op CF | 5.0B | 4.6B | 4.4B | 5.0B | -0.2% | 5.0B | — | — | — |
| Inv CF | -3.8B | -3.2B | -2.5B | -629.1M | — | — | — | — | — |
| Fin CF | -1.0B | -1.8B | -2.2B | -3.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc.(you) | $68.8B | 84 | STRONG BUY |
| 688235.SS | BeOne Medicines AG | $46.1B | 78 | BUY |
| ARGX | argenx SE | $57.1B | 70 | BUY |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $127.2B | 89 | STRONG BUY |
| UCB.BR | UCB SA | $56.0B | 64 | HOLD |
| RPRX | Royalty Pharma plc | $33.9B | 70 | BUY |
| 0J9P.L | Incyte Corporation | $20.6B | 88 | STRONG BUY |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $17.3B | 88 | STRONG BUY |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.1%